- Home
- GNTA vs EVAX Comparison
GNTA vs EVAX Comparison
Compare GNTA & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNTA | EVAX |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | Italy | Denmark |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0M | 27.4M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | GNTA | EVAX |
|---|---|---|
| Price | $0.88 | $4.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | ★ 53.4K | 26.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.71 | $1.20 |
| 52 Week High | $10.00 | $12.15 |
Technical Indicators
Market Signals| Indicator | GNTA | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 39.45 | 64.00 |
| Support Level | $0.71 | $2.70 |
| Resistance Level | $1.70 | $5.48 |
| Average True Range (ATR) | 0.08 | 0.32 |
| MACD | 0.01 | 0.16 |
| Stochastic Oscillator | 17.75 | 76.06 |
Price Performance
Historical ComparisonAbout GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About EVAX Evaxion Biotech
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.